1993
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer.
Murren J, Ganpule S, Papac R, Son Y, Peschel R, Durivage H, Buzaid A, Lamb L, Makuch R, Hait W. A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 1993, 5: 53-7. PMID: 8395915.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerMedian survival timeMitomycin CComplete respondersLung cancerSurvival timeUnresectable stage III non-small cell lung cancerStage III non-small cell lung cancerUnresectable non-small cell lung cancerDay 1Concurrent mitomycin CPhase II trialOverall response rateX-irradiationModerate stomatitisSustained remissionII trialSplit courseWeek restMedian durationContinuous infusionSimultaneous administrationRadiation therapyResponse rate
1991
myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens.
Brennan J, O'Connor T, Makuch R, Simmons A, Russell E, Linnoila R, Phelps R, Gazdar A, Ihde D, Johnson B. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Research 1991, 51: 1708-12. PMID: 1847842.Peer-Reviewed Original ResearchConceptsMyc family DNA amplificationSmall cell lung cancerCell lung cancerLung cancerTumor cell linesExtensive-stage small-cell lung cancer patientsSmall cell lung cancer patientsCell linesPatient specimensCell lung cancer patientsDNA copy numberDifferent combination chemotherapyEtoposide/cisplatinDifferent chemotherapy regimensInitiation of therapyLung cancer patientsFrequency of amplificationChemotherapy regimensUntreated patientsCombination chemotherapyCancer patientsSame patientPatientsClinical situationsDNA amplification
1990
Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation.
Johnson B, Grayson J, Makuch R, Linnoila R, Anderson M, Cohen M, Glatstein E, Minna J, Ihde D. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Journal Of Clinical Oncology 1990, 8: 396-401. PMID: 2155310, DOI: 10.1200/jco.1990.8.3.396.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerLung cancerLung cancer 2Initiation of chemotherapyTen-year survivalCell lung cancerTherapeutic clinical trialsCranial irradiationCombination chemotherapyOriginal malignancySecond cancersClinical trialsHigh riskPatientsCancer 2CancerChemotherapyMalignancyMore yearsCauseYearsChestDiagnosisTrials
1988
Identifying prognostic factors in binary outcome data: An application using liver function tests and age to predict liver metastases
Makuch R, Rosenberg P, Mulshine J. Identifying prognostic factors in binary outcome data: An application using liver function tests and age to predict liver metastases. Statistics In Medicine 1988, 7: 843-856. PMID: 2842852, DOI: 10.1002/sim.4780070803.Peer-Reviewed Original ResearchConceptsLiver function testsLiver metastasesFunction testsOutcome dataSmall cell lung cancerImportant prognostic variablesCell lung cancerLogistic regression modelsPrognostic factorsLung cancerPrognostic variablesMetastasisBinary outcome dataSpecific guidelinesRegression modelsAgeStandard logistic regression model
1986
Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene.
Johnson B, Battey J, Linnoila I, Becker K, Makuch R, Snider R, Carney D, Minna J. Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene. Journal Of Clinical Investigation 1986, 78: 525-532. PMID: 3016030, PMCID: PMC423589, DOI: 10.1172/jci112604.Peer-Reviewed Original ResearchConceptsSmall cell lung cancer cell linesCell lung cancer cell linesLung cancer cell linesCancer cell linesBombesin-like immunoreactivityLarge cell morphologyC-myc messenger RNAC-myc expressionC-MycCell linesSmall cell lung cancerHuman small cell lung cancer cell linesCell lung cancerSmall cell lung cancer linesCell lung cancer linesMessenger RNALung cancer linesC-myc amplificationC-myc geneLung cancerVariant phenotypesCloning efficiencyDecarboxylase levelsCancer linesBiologic propertiesNon-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer
Johnson B, Ihde D, Matthews M, Bunn P, Zabell A, Makuch R, Johnston-early A, Cohen M, Glatstein E, Minna J. Non-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer. The American Journal Of Medicine 1986, 80: 1103-1110. PMID: 3014875, DOI: 10.1016/0002-9343(86)90672-8.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerLung cancer deathsLung cancerCancer deathSame lobeSecond primary lung tumorsCancer-free survivorsDisease-free survivalPrimary lung tumorsSecond malignant tumorsRisk of developmentLate mortalityContralateral lungTherapeutic trialsInitial lesionLung tumorsMalignant tumorsHigh riskPatientsCancerDifferent lobesMajor causeDiagnosisStudy of menPulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.
Brooks B, Seifter E, Walsh T, Lichter A, Bunn P, Zabell A, Johnston-Early A, Edison M, Makuch R, Cohen M. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 200-9. PMID: 3003259, DOI: 10.1200/jco.1986.4.2.200.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyCyclophosphamideDoxorubicinFemaleHumansLomustineLung NeoplasmsMaleMethotrexateMiddle AgedProcarbazinePrognosisProspective StudiesPulmonary FibrosisRadiographyRandom AllocationRespiratory Function TestsVincristineConceptsPulmonary function testsLimited stage small cell lung cancerStage small cell lung cancerSmall cell lung cancerModality therapyPulmonary toxicityPulmonary complicationsVital capacityLung cancerRadiation therapyLife-threatening pulmonary toxicityInitial pulmonary function testLower vital capacitySubsequent pulmonary complicationsBilateral pulmonary infiltratesDisease-free survivalModality armPulmonary infiltratesPulmonary morbidityExpiratory volumeOverall survivalPerformance statusProspective trialClinical courseHospital admission
1985
Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up.
Johnson B, Ihde D, Bunn P, Becker B, Walsh T, Weinstein Z, Matthews M, Whang-Peng J, Makuch R, Johnston-Early A. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Annals Of Internal Medicine 1985, 103: 430-8. PMID: 2992337, DOI: 10.7326/0003-4819-103-3-430.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrainCarcinoma, Small CellCombined Modality TherapyFemaleFollow-Up StudiesHematologic DiseasesHumansLung NeoplasmsMaleMemory DisordersMiddle AgedNeoplasm Recurrence, LocalNervous System DiseasesRadiotherapyRespiratory Function TestsConceptsSmall cell lung cancerLung cancerCombination chemotherapyEvidence of cancerCancer-free survivalCell lung cancerCranial irradiationAggressive therapyLate toxicityUnrelated causesLate relapseTherapeutic trialsCancer 5PatientsPotential cureThirty-monthCancerChemotherapyRelapseCureChronic toxicityMonthsSurvivalEleven yearsToxicityThe role of radiation therapy in the treatment of small cell lung cancer
Lichter A, Bunn P, Ihde D, Cohen M, Makuch R, Carney D, Johnston‐Early A, Minna J, Glatstein E. The role of radiation therapy in the treatment of small cell lung cancer. Cancer 1985, 55: 2163-2175. PMID: 2983875, DOI: 10.1002/1097-0142(19850501)55:9+<2163::aid-cncr2820551420>3.0.co;2-y.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsCarcinoma, Small CellClinical Trials as TopicCombined Modality TherapyCyclophosphamideDoxorubicinFollow-Up StudiesHumansLomustineLung NeoplasmsMethotrexateProcarbazineProspective StudiesRadiotherapyRadiotherapy DosageRandom AllocationTime FactorsVincristineWhole-Body IrradiationConceptsSmall cell lung cancerLimited-stage small cell lung cancerProphylactic cranial irradiationCell lung cancerCranial irradiationThoracic irradiationLung cancerExtensive-stage small-cell lung cancerComplete response statusLimited-stage diseaseOptimal treatment approachCombination of chemotherapyMinimum of toxicityLong-term survivalSystemic irradiationSystemic chemotherapyAggressive therapyPartial responseCNS failureResponse statusTreatment protocolOngoing protocolRadiation therapyTreatment approachesPatientsA COMPARISON OF COMPUTED TOMOGRAPHY AND RADIONUCLIDE SCANNING FOR DETECTION OF BRAIN METASTASES IN SMALL CELL LUNG CANCER
Crane J, Nelson M, Ihde D, Makuch R, Glatstein E, Zabell A, Johnston-Early A, Bates H, Saini N, Cohen M, Bunn P. A COMPARISON OF COMPUTED TOMOGRAPHY AND RADIONUCLIDE SCANNING FOR DETECTION OF BRAIN METASTASES IN SMALL CELL LUNG CANCER. Journal Of Computer Assisted Tomography 1985, 9: 643. DOI: 10.1097/00004728-198505000-00085.Peer-Reviewed Original Research
1984
Elevated serum creatine kinase BB levels in patients with small cell lung cancer.
Carney D, Zweig M, Ihde D, Cohen M, Makuch R, Gazdar A. Elevated serum creatine kinase BB levels in patients with small cell lung cancer. Cancer Research 1984, 44: 5399-403. PMID: 6091876.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerSerum CK-BBSerum CK-BB levelsCK-BB levelsCell lung cancerMetastatic sitesLung cancerCK-BBCreatine kinase BB levelsExtensive-stage diseaseSCLC cell linesClinical tumor specimensLimited diseaseClinical responseExtensive diseaseMetastatic diseaseUntreated patientsPretreatment stagingTumor disseminationTumor specimensPatientsBB isoenzymeBb levelsSignificant associationCreatine kinaseA comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer.
Crane J, Nelson M, Ihde D, Makuch R, Glatstein E, Zabell A, Johnston-Early A, Bates H, Saini N, Cohen M. A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer. Journal Of Clinical Oncology 1984, 2: 1017-24. PMID: 6088707, DOI: 10.1200/jco.1984.2.9.1017.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerRadionuclide brain scanCell lung cancerBrain metastasesCT scanBrain scansAsymptomatic patientsNeurologic signsLung cancerExtensive-stage diseaseTherapeutic cranial irradiationTomographic brain scansCT brain scanSix-month intervalsCranial irradiationRN scansSCLC patientsAsymptomatic lesionsSymptomatic patientsSystemic therapyConsecutive patientsNeurologic historyComputed tomographyPatientsMetastasisDiagnosis and significance of liver metastases in small cell carcinoma of the lung.
Mulshine J, Makuch R, Johnston-Early A, Matthews M, Carney D, Ihde D, Cohen M, Bates H, Dunnick N, Minna J. Diagnosis and significance of liver metastases in small cell carcinoma of the lung. Journal Of Clinical Oncology 1984, 2: 733-41. PMID: 6330314, DOI: 10.1200/jco.1984.2.7.733.Peer-Reviewed Original ResearchConceptsLiver function testsLiver metastasesLiver biopsyLiver scanFunction testsLiver evaluationSmall cell lung cancerNoninvasive procedureDisease-free survivorsPercutaneous liver biopsySmall cell carcinomaCell lung cancerRadionuclide liver scanResponse of patientsNational Cancer InstituteSuch metastasesLiver involvementConsecutive patientsStaging procedureHepatic metastasesPrognostic implicationsCell carcinomaPhysical examinationLung cancerCancer Institute
1983
Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer
Johnston‐Early A, Cohen M, Fossieck B, Harwood S, Ihde D, Bunn P, Matthews M, Minna J, Makuch R. Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. Cancer 1983, 52: 1395-1400. PMID: 6311393, DOI: 10.1002/1097-0142(19831015)52:8<1395::aid-cncr2820520810>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsSkin test reactivityGood performance statusLow tumor burdenTest reactivityAnergic patientsPerformance statusTumor burdenReactive patientsSmall cell lung cancer patientsHypersensitivity skin test reactivityCell lung cancer patientsSmall cell lung cancerGood prognosis patientsHypersensitivity skin testingCell lung cancerLung cancer patientsSkin test antigensPrognosis patientsSkin testingPoor prognosisPrognostic importancePrognostic utilityPrognostic indicatorCancer patientsLung cancer
1982
Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer.
Minna J, Bunn P, Carney D, Cohen M, Cuttita F, Fosieck B, Gazdar A, Ihde D, Johnston-Early A, Matthews M, Makuch R, Oie H, Rosen S, Lichter A, Glatstein E. Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer. Bulletin Du Cancer 1982, 69: 83-93. PMID: 6280795.Peer-Reviewed Original Research
1981
Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer.
Cohen M, Makuch R, Johnston-Early A, Ihde D, Bunn P, Fossieck B, Minna J. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Journal Of The National Cancer Institute 1981, 65: 187-95. PMID: 6263468.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerLaboratory parametersLung cancerPerformance statusPrognostic factorsPrognostic indexSmall cell anaplastic lung cancerInfluential prognostic factorObjective prognostic indexPretreatment performance statusMajor prognostic factorSelf-limited eventAlpha-1 globulinCancer clinical trialsLaboratory resultsSignificant prognosticatorMedian followupAlbumin levelsMinimum followupPrognostic stratificationSurvival durationClinical trialsHigher hemoglobinTreatment response
1980
Smoking Abstinence and Small Cell Lung Cancer Survival: An Association
Johnston-Early A, Cohen M, Minna J, Paxton L, Fossieck B, Ihde D, Bunn P, Matthews M, Makuch R. Smoking Abstinence and Small Cell Lung Cancer Survival: An Association. JAMA 1980, 244: 2175-2179. DOI: 10.1001/jama.1980.03310190027016.Peer-Reviewed Original ResearchSmall cell lung cancerCell lung cancerSS patientsLung cancerCell lung cancer survivalThymosin fraction V.Lung cancer survivalDiscontinuation of smokingStart of treatmentContinuation of smokingSurvival benefitCigarette smokingPoor prognosisPrognostic implicationsCancer survivalSmoking abstinenceSurvival differencesRadiation therapyBetter survivalPatientsSmokingBeneficial effectsS groupDiagnosisSurvivalSmoking abstinence and small cell lung cancer survival. An association.
Johnston-Early A, Cohen M, Minna J, Paxton L, Fossieck B, Ihde D, Bunn P, Matthews M, Makuch R. Smoking abstinence and small cell lung cancer survival. An association. JAMA 1980, 244: 2175-9. PMID: 6252357, DOI: 10.1001/jama.244.19.2175.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerSS patientsLung cancerCell lung cancer survivalThymosin fraction V.Lung cancer survivalDiscontinuation of smokingStart of treatmentContinuation of smokingSurvival benefitCigarette smokingPoor prognosisPrognostic implicationsCancer survivalSurvival differencesRadiation therapyBetter survivalPatientsSmokingBeneficial effectsS groupDiagnosisSurvivalTherapy
1979
Thymosin Fraction V and Intensive Combination Chemotherapy: Prolonging the Survival of Patients With Small-Cell Lung Cancer
Cohen M, Chretien P, Ihde D, Fossieck B, Makuch R, Bunn P, Johnston A, Shackney S, Matthews M, Lipson S, Kenady D, Minna J. Thymosin Fraction V and Intensive Combination Chemotherapy: Prolonging the Survival of Patients With Small-Cell Lung Cancer. JAMA 1979, 241: 1813-1815. DOI: 10.1001/jama.1979.03290430031019.Peer-Reviewed Original ResearchThymosin fraction VIntensive remission induction chemotherapySmall cell bronchogenic carcinomaSmall cell lung cancerComplete response rateRemission induction chemotherapyWeeks of chemotherapyIntensive combination chemotherapySurvival of patientsRelapse-free survivalThymosin administrationThymosin treatmentComplete respondersCombination chemotherapyBronchogenic carcinomaImmune deficitsLung cancerSurvival durationSurvival timeTreatment groupsResponse rateChemotherapyPatientsFraction VTreatmentThymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer.
Cohen M, Chretien P, Ihde D, Fossieck B, Makuch R, Bunn P, Johnston A, Shackney S, Matthews M, Lipson S, Kenady D, Minna J. Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer. JAMA 1979, 241: 1813-5. PMID: 219267, DOI: 10.1001/jama.241.17.1813.Peer-Reviewed Original ResearchConceptsThymosin fraction VIntensive remission induction chemotherapySmall cell bronchogenic carcinomaSmall cell lung cancerComplete response rateRemission induction chemotherapyWeeks of chemotherapyIntensive combination chemotherapySurvival of patientsRelapse-free survivalThymosin administrationThymosin treatmentComplete respondersCombination chemotherapyBronchogenic carcinomaImmune deficitsLung cancerSurvival durationSurvival timeTreatment groupsResponse rateChemotherapyPatientsFraction VTreatment